VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 27, 2015 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it will release its year-end financial results for the fiscal year ending June 30, 2015 on Friday, September 4, 2015.
DelMar's management team will host a business update conference call and live webcast for investors, analysts and other interested parties on Friday, September 4, 2015, at 11:00 a.m. EDT / 8:00 a.m. PDT.
During the business update call, management will discuss recent corporate highlights including the Company's progress of its Phase II clinical trial of VAL-083 (dianhydrogalactitol) for the treatment of refractory glioblastoma multiforme (GBM) and corporate goals for the upcoming year including plans to advance VAL-083 into registration-directed Phase II/III clinical trials in refractory GBM as well as initiate new clinical trials with VAL-083 as a potential treatment for non-small cell lung cancer (NSCLC) and other solid tumors.
Conference Call Details
The DelMar business update conference call and live webcast is scheduled for Friday, September 4, 2015, beginning at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time.
DMPI